Immunogenicity of a Single Dose of Tetravalent Meningococcal Serogroups A, C, W-135, and Y Conjugate Vaccine Administered to 2- to 10-year-olds Is Noninferior to a Licensed-ACWY Polysaccharide Vaccine With an Acceptable Safety Profile
暂无分享,去创建一个
A. Dubey | Z. Memish | S. Gatchalian | G. Dbaibo | M. van der Wielen | V. Verghese | H. Jain | V. Bianco | Jacqueline M. Miller | May Montellano | M. Wielen
[1] A. Pollard,et al. The epidemiology of meningococcal disease and the impact of vaccines , 2010, Expert review of vaccines.
[2] W. Schaffner,et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] J. Poolman,et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. , 2010, Vaccine.
[4] K. Reisinger,et al. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] Lee H Harrison,et al. Global epidemiology of meningococcal disease. , 2009, Vaccine.
[6] S. Gupta,et al. Ciprofloxacin-Resistant Neisseria meningitidis, Delhi, India , 2007, Emerging infectious diseases.
[7] N. Gogtay,et al. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. , 2007, Vaccine.
[8] R. Hajjeh,et al. The epidemiology of pneumococcal, meningococcal, and Haemophilus disease in the Middle East and North Africa (MENA) region--current status and needs. , 2007, Vaccine.
[9] S. Chanteau,et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] H. Keyserling,et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. , 2005, Archives of pediatrics & adolescent medicine.
[11] E. Miller,et al. Meningococcal surrogates of protection--serum bactericidal antibody activity. , 2005, Vaccine.
[12] M. Patel,et al. Polysaccharide vaccines for preventing serogroup A meningococcal meningitis. , 2005, The Cochrane database of systematic reviews.
[13] M. Pichichero,et al. Comparative Trial of the Safety and Immunogenicity of Quadrivalent (A, C, Y, W-135) Meningococcal Polysaccharide-Diphtheria Conjugate Vaccine Versus Quadrivalent Polysaccharide Vaccine in Two- to Ten-Year-Old Children , 2005, The Pediatric infectious disease journal.
[14] A. Pollard. Global Epidemiology of Meningococcal Disease and Vaccine Efficacy , 2004, The Pediatric infectious disease journal.
[15] Y. Al-Mazrou,et al. Disease burden and case management of bacterial meningitis among children under 5 years of age in Saudi Arabia. , 2003, Saudi medical journal.
[16] N. Andrews,et al. Validation of Serological Correlate of Protection for Meningococcal C Conjugate Vaccine by Using Efficacy Estimates from Postlicensure Surveillance in England , 2003, Clinical Diagnostic Laboratory Immunology.
[17] K. Goh,et al. Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] N. Andrews,et al. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis , 2003, BMJ : British Medical Journal.
[19] J. T. Koama,et al. Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso. , 2002, The Lancet. Infectious diseases.
[20] Fonkoua Mc. Meningococcal meningitis in Africa. , 2002, Releve epidemiologique hebdomadaire.
[21] M. Achtman,et al. Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana. , 2002, The Journal of infectious diseases.
[22] R. Kanungo,et al. Childhood bacterial meningitis in Pondicherry, South India , 2001, Indian journal of pediatrics.
[23] K. Cartwright,et al. Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, 6-8 October, 2000. , 2001, Vaccine.
[24] T. Popović,et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. , 1999, The Journal of infectious diseases.
[25] B. Greenwood,et al. Manson Lecture. Meningococcal meningitis in Africa. , 1999, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[26] J. Taylor,et al. Efficacy of meningococcal vaccine and barriers to vaccination. , 1998, JAMA.
[27] G. Carlone,et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group , 1997, Clinical and diagnostic laboratory immunology.
[28] Meningitis in Chad, Niger and Nigeria: 2009 epidemic season. , 2010, Releve epidemiologique hebdomadaire.
[29] Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010. , 2010, MMWR. Morbidity and mortality weekly report.
[30] J. Poolman,et al. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. , 2009, Vaccine.
[31] Inadvertent misadministration of meningococcal conjugate vaccine--United States, June-August 2005. , 2006, MMWR. Morbidity and mortality weekly report.
[32] D. Goldblatt,et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. , 2001, The Journal of infectious diseases.
[33] S. Jaffar,et al. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. , 1997, The Journal of infectious diseases.
[34] G. Carlone,et al. Standardization and a Multilaboratory Comparison ofNeisseria meningitidisSerogroup A and C Serum Bactericidal Assays , 1997 .
[35] Peltola,et al. Control of Epidemic Meningococcal Disease. Who Practical Guidelines. 2 World Health Organization Emerging and Other Communicable Diseases, Surveillance and Control Editorial Working Group Preface (edition 1) Preface (edition 1) , 2022 .